Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective

Journal of Surgical Oncology

Volumn 109, Issue 2, 2014, Pages 95-97

  Sullivan, Kevin M ^a   Groeschl, Ryan T ^a   Turaga, Kiran K ^a   Tsai, Susan ^a   Christians, Kathleen K ^a   White, Sarah B ^a   Rilling, William S ^a   Pilgrim, Charles H C ^a   Gamblin, T Clark ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

hepatocellular carcinoma; inflammation; neutrophil to lymphocyte ratio

Indexed keywords

ADULT; AGED; ASIA; CANCER PATIENT; CHEMOEMBOLIZATION; CHILD PUGH SCORE; EUROPE; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; NEUTROPHIL COUNT; NEUTROPHIL TO LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SHORT TERM SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION; VERY ELDERLY; YOUNG ADULT;

HEPATOCELLULAR CARCINOMA; INFLAMMATION; NEUTROPHIL-TO-LYMPHOCYTE RATIO;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84892938594     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23448     Document Type: Review

References (23)

1. El-Serag HB:, Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Camma C, Cabibbo G:, Prognostic scores for hepatocellular carcinoma: None is the winner. Liver Int 2009; 29: 478-480.
3. Shetty K, Timmins K, Brensinger C, et al.: Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918.
4. Shah SA, Tan JC, McGilvray ID, et al.: Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006; 81: 1633-1639.
5. Balkwill F, Mantovani A:, Inflammation and cancer: Back to virchow ? Lancet 2001; 357: 539-545.
6. Coussens LM, Werb Z:, Inflammation and cancer. Nature 2002; 420: 860-867.
7. Grivennikov SI, Greten FR, Karin M:, Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
8. Walsh SR, Cook EJ, Goulder F, et al.: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.
9. Kishi Y, Kopetz S, Chun YS, et al.: Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16: 614-622.
10. Sharaiha RZ, Halazun KJ, Mirza F, et al.: Elevated preoperative neutrophil: Lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011; 18: 3362-3369.
11. Shimada H, Takiguchi N, Kainuma O, et al.: High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13: 170-176.
12. Gomez D, Morris-Stiff G, Toogood GJ, et al.: Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2008; 97: 513-518.
13. Wang GY, Yang Y, Li H, et al.: A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS ONE 2011; 6: e25295.
14. Bertuzzo VR, Cescon M, Ravaioli M, et al.: Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91: 1279-1285.
15. Gomez D, Farid S, Malik HZ, et al.: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757-1762.
16. Huang ZL, Luo J, Chen MS, et al.: Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011; 22: 702-709.
17. Kinoshita A, Onoda H, Imai N, et al.: Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer 2012; 107: 988-993.
18. Yuen MF, Hou JL, Chutaputti A:, Asia pacific working party on prevention of hepatocellular carcinoma. Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol 2009; 24: 346-353.
19. El-Serag HB:, Hepatocellular carcinoma: Recent trends in the united states. Gastroenterology 2004; 127: S27-S34.
20. Young AL, Adair R, Prasad KR, et al.: Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: Surgical approaches and outcomes. J Am Coll Surg 2012; 214: 174-183.
21. Oh BS, Jang JW, Kwon JH, et al.: Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer 2013; 13: 78.
22. Bruix J, Sherman M:, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
23. Llovet JM, Bru C, Bruix J:, Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.